Clazakizumab vs placebo or usual care
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.91 [0.54, 1.55]2 studies · 169 participantsVery low